Volume 12, Number 2—February 2006
Letter
Borrelia burgdorferi and Anaplasma phagocytophilum Coinfection
Table
Results of serologic tests at diagnosis and during follow-up*
Time (d) after onset of symptoms | Anaplasma (Ehrlichia) phagocytophilum (IFA)† |
Borrelia burgdorferi (ELISA)‡ |
Borrelia burgdorferi (Immunoblot)§ |
|||
---|---|---|---|---|---|---|
IgM | IgG | IgM | IgG | IgM | IgG | |
6 | Negative (<1:20) | Negative (<1:32) | Negative | Negative | Negative | Negative |
10 | ND | ND | Positive | Negative | ND | ND |
28 | Positive (1:40) | Negative (1:32) | Positive | Negative | Positive | Negative |
107 | Positive (1:20) | Negative (<1:32) | Positive | Negative | Positive | Negative |
380 | Negative (<1:20) | Negative (<1:32) | Equivocal | Negative | Positive | Negative |
*Symptoms (fever, headache, myalgia) started 6 days before presentation. IFA, immunofluorescent assay; ELISA, enzyme-linked immunosorbent assay; Ig, immunoglobulin; ND, not done.
†Genzyme Virotech, Germany. Positive titers: IgM >1:20, IgG >1:64.
‡Behring, Germany.
§In-house Immunoblot, Max von Pettenkofer-Institut, Munich, Germany.
Page created: February 02, 2012
Page updated: February 02, 2012
Page reviewed: February 02, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.